Catalyst Pharmaceuticals, Inc.
CPRXNASDAQHealthcare● Active
$31.28
+$0.01(+0.03%)
Market Cap$3.8B
P/E Ratio—
52W High$32.56
52W Low$19.05
Catalyst Pharmaceuticals, Inc. (CPRX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CPRX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.21B | $0.16B | $0.07B | $0.08B | $0.04B |
| Depreciation & Amort. | $0.04B | $0.04B | $0.03B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.02B | $0.02B | $0.01B | $0.01B | $0.01B |
| Change in Working Capital | ($0.06B) | $0.03B | ($0.04B) | $0.01B | $0.01B |
| Net Cash from Operations | $0.21B | $0.24B | $0.14B | $0.12B | $0.06B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.08B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | $0.00B | $0.00B | ($0.01B) | ($0.01B) | ($0.01B) |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.02B | $0.00B |
| Net Cash from Investing | ($0.00B) | ($0.00B) | ($0.29B) | $0.01B | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.03B) | ($0.00B) | $0.00B | ($0.01B) | ($0.01B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.02B) | $0.14B | ($0.01B) | $0.00B | ($0.01B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.21B | $0.24B | $0.06B | $0.12B | $0.06B |
| FCF Margin %(computed) | 35.42% | 48.65% | 15.53% | 54.16% | 42.14% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Catalyst Pharmaceuticals, Inc. data
About Catalyst Pharmaceuticals, Inc. (CPRX) Cash Flow Statement
Catalyst Pharmaceuticals, Inc. generated operating cash flow of $0.21B and free cash flow of $0.21B for 2025 — a FCF margin of 35.42%. Capital expenditure was ($0.00B).
Frequently asked questions
CPRX · 4 questionsCatalyst Pharmaceuticals, Inc. generated free cash flow of $0.21B for 2025, down 12.8% year-over-year.
CPRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10